Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era.

Taylor, Richard S

Taylor, Richard S.

Taylor RS; Neonatologist, Victoria General Hospital, Victoria, BC.

CMAJ ; 193(15): E523, 2021 04 12.

Article in English | MEDLINE | ID: covidwho-1181206

Subject(s)

Antiviral Agents/therapeutic use; Palivizumab/therapeutic use; Respiratory Syncytial Virus Infections/prevention & control; COVID-19/epidemiology; Canada/epidemiology; Humans; Infant; Pandemics; Practice Guidelines as Topic; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Respiratory Syncytial Virus Infections / Palivizumab Type of study: Observational study / Prognostic study Limits: Humans / Infant Country/Region as subject: North America Language: English Journal: CMAJ Journal subject: Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google